- Our World
- Our Business
- Life at Lupin
- Global Sites
Lupin's IPMG has been responsible for creating, cultivating, leveraging and securing an ever growing portfolio of high-value patents, product and research pipeline. Its IPMG has been carrying out patent litigations and challenges successfully.
The Company was first-to-file with respect to generic versions of Nascobal® Nasal Spray, Triumeq® Tablets, Trintellix® Tablets, Bromsite® Ophthalmic Solution, Aptiom® Tablets, Farxiga® Tablets, Xigduo XR® Tablets and Qtern® Tablets
Cumulative ANDA and NDA filings with US FDA now stand at 402 with 239 approvals till date. Lupin now has a total of 36 FTF ANDAs pending which includes 15 exclusive FTF opportunities
The company settled 7 pending patent litigations during the year and received favourable decisions on Vivlodex®, Effient®, Locoid®, Axiron®
In FY2018, the Company ﬁled 208 patent applications, including 53 new inventions. The cumulative total number of patents ﬁled by Lupin in India and other countries to date is 3,045. The patent applications ﬁled in FY2018 included 32 formulation patents, 75 API/process patents, 21 biotech patents and 80 NDDD patents. We successfully secured 63 patents, including 34 NDDD patents during the year.